Detail akcie Appili Therap Rg-A online

Business Summary: Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
Financial Summary: BRIEF: For the three months ended 30 June 2025, Appili Therapeutics Inc revenues was not reported. Net loss decreased 21% to C$1.2M. Lower net loss reflects Research and development - Remaining decrease of 73% to C$370K (expense), Financing costs decrease of 61% to C$486K (expense), Foreign exchange loss/(gain) increase from C$57K (expense) to C$320K (income). Basic Earnings per Share excluding Extraordinary Items remained flat at -C$0.01.